{"entity":{"id":"umrd","kind":"term","name":"Undetectable MRD (uMRD / MRD-negative)","aka":["uMRD","MRD-negative","MRD negative","MRD negativity rate","MRD-positive","MRD positive","MRD-persistent","MRD persistence","MRD-guided","MRD-driven","MRD-adapted","sustained MRD negativity","uMRD4","MRD 10^-5","MRD 10-6"],"tldr":"The test for leftover cancer cells found none, down to the sensitivity of the assay (often one cell in 100,000 or a million). It is the deepest remission we can measure and is becoming a treatment goal and trial endpoint in blood cancers.","summary":"In CLL, undetectable MRD at the end of fixed-duration venetoclax therapy predicts years off treatment and defines when to stop; in myeloma, MRD negativity at 10^-5 or 10^-6 (by next-generation flow or sequencing) is accepted by the FDA as an early endpoint for accelerated approval and guides de-escalation trials; in ALL, converting MRD-positive to negative with blinatumomab (BLAST) was the basis of its approval; in AML, NPM1 or flow MRD decides who needs transplant. MRD-positive after therapy predicts relapse and triggers intensification. The depth (10^-4 versus 10^-6) matters and assays are not interchangeable.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Minimal_residual_disease","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Minimal_residual_disease"}],"tags":[],"related":["mrd","flow-cytometry","fixed-duration","complete-response-term"],"cancers":["cll","multiple-myeloma","all-leukemia","aml"],"sections":["diagnostics"],"technologies":["mrd-testing"],"targets":[],"drugs":["venetoclax","blinatumomab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Biomarkers"},"route":"/terms/umrd/","neighbours":{"term":[{"id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/"},{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/"},{"id":"de-escalation","kind":"term","name":"De-escalation, escalation and response-adapted therapy","route":"/terms/de-escalation/"},{"id":"fixed-duration","kind":"term","name":"Fixed-duration vs continuous therapy","route":"/terms/fixed-duration/"},{"id":"flow-cytometry","kind":"term","name":"Flow cytometry (immunophenotyping)","route":"/terms/flow-cytometry/"},{"id":"m-protein-free-light-chains","kind":"term","name":"M-protein, immunofixation and serum free light chains","route":"/terms/m-protein-free-light-chains/"},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"molecular-response","kind":"term","name":"Molecular response (MMR, MR4, treatment-free remission)","route":"/terms/molecular-response/"},{"id":"vrd","kind":"term","name":"VRd and Dara-VRd (myeloma induction regimens)","route":"/terms/vrd/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"},{"id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}]}}